BACKGROUND AND AIMS: Little is known about the epidemiology of malignant digestive endocrine tumours. The aim of this study was to report on their incidence and management in a well defined population. METHODS: Data were obtained from the population based Digestive Cancer Registry of Burgundy (France) over a 24 year period. Incidence rates were calculated by sex, age groups, and period of diagnosis. Treatment and stage at diagnosis were also investigated. Prognosis was determined using crude and relative survival rates. A multivariate relative survival analysis was performed. RESULTS: Between 1976 and 1999, 229 cases were recorded. Age standardised incidence rates were 0.76/100,000 for men and 0.50/100,000 for women. They increased over time in both sexes. The resectability rate was 74.1%. Among recorded cases, 26.6% did not extend beyond the organ, 20% had lymph node metastases, and 53.3% had visceral metastases or were unresectable. There was no improvement in the resection rate or in the stage at diagnosis over the study period. The overall relative survival rate was 66.9% at one year, 50.4% at five years, and 40.6% at 10 years. Stage at diagnosis, age at diagnosis, and subsite were independent significant prognostic factors. CONCLUSIONS: Although their incidence is increasing, malignant digestive endocrine tumours remain a rare cancer, representing 1% of digestive cancers. Stage at diagnosis and prognosis at a population level are worse than those reported in hospital series. In the short term, new therapeutic possibilities represent the best way to improve their prognosis.
BACKGROUND AND AIMS: Little is known about the epidemiology of malignant digestive endocrine tumours. The aim of this study was to report on their incidence and management in a well defined population. METHODS: Data were obtained from the population based Digestive Cancer Registry of Burgundy (France) over a 24 year period. Incidence rates were calculated by sex, age groups, and period of diagnosis. Treatment and stage at diagnosis were also investigated. Prognosis was determined using crude and relative survival rates. A multivariate relative survival analysis was performed. RESULTS: Between 1976 and 1999, 229 cases were recorded. Age standardised incidence rates were 0.76/100,000 for men and 0.50/100,000 for women. They increased over time in both sexes. The resectability rate was 74.1%. Among recorded cases, 26.6% did not extend beyond the organ, 20% had lymph node metastases, and 53.3% had visceral metastases or were unresectable. There was no improvement in the resection rate or in the stage at diagnosis over the study period. The overall relative survival rate was 66.9% at one year, 50.4% at five years, and 40.6% at 10 years. Stage at diagnosis, age at diagnosis, and subsite were independent significant prognostic factors. CONCLUSIONS: Although their incidence is increasing, malignant digestive endocrine tumours remain a rare cancer, representing 1% of digestive cancers. Stage at diagnosis and prognosis at a population level are worse than those reported in hospital series. In the short term, new therapeutic possibilities represent the best way to improve their prognosis.
Authors: V D Corleto; F Panzuto; M Falconi; R Cannizzaro; S Angeletti; A Moretti; G Delle Fave; F Farinati Journal: Dig Liver Dis Date: 2001-04 Impact factor: 4.088
Authors: Steven N Hochwald; Sui Zee; Kevin C Conlon; Roberto Colleoni; Otway Louie; Murray F Brennan; David S Klimstra Journal: J Clin Oncol Date: 2002-06-01 Impact factor: 44.544
Authors: Patrick Veit-Haibach; Marc Schiesser; Jan Soyka; Klaus Strobel; Niklaus G Schaefer; Rolf Hesselmann; P-A Clavien; Thomas F Hany Journal: Eur Radiol Date: 2010-08-15 Impact factor: 5.315
Authors: Srinivas R Puli; Nikhil Kalva; Matthew L Bechtold; Smitha R Pamulaparthy; Micheal D Cashman; Norman C Estes; Richard H Pearl; Fritz-Henry Volmar; Sonu Dillon; Michael F Shekleton; David Forcione Journal: World J Gastroenterol Date: 2013-06-21 Impact factor: 5.742
Authors: Nicola Fazio; Roberto Buzzoni; Eric Baudin; Lorenzo Antonuzzo; Richard A Hubner; Harald Lahner; Wouter W DE Herder; Markus Raderer; Alexandre Teulé; Jaume Capdevila; Steven K Libutti; Matthew H Kulke; Manisha Shah; Debarshi Dey; Sabine Turri; Paola Aimone; Cristian Massacesi; Chris Verslype Journal: Anticancer Res Date: 2016-02 Impact factor: 2.480